The first participants have been dosed in the initial part of a Phase 1 clinical trial evaluating the investigational compound CST-2032 as a treatment for neurodegenerative disease, according to the therapy’s developers, CuraSen Therapeutics. The trial will enroll up to 70 healthy volunteers and patients with a variety…
Nearly a quarter of patients with Parkinson’s disease polled in a U.S. national survey reported using cannabis mainly to try and ease their symptoms, despite a lack of evidence on both its effectiveness and safety. Although still federally illegal, marijuana has been legalized for either recreational or medicinal…
One-time treatment with investigational gene therapy VY-AADC (NBIb-1817) showed sustained improvement in motor function in patients with Parkinson’s, results from the Phase 1 PD-1102 clinical trial show. These results were presented recently in two poster presentations at the MDS Virtual Congress 2020. VY-AADC, a gene therapy being…
Lower-than-usual levels of the protein SIRT1 are evident in the blood of people with Parkinson’s disease, and correlate with greater disease severity and cognitive impairment, a study reported. A blood test of SIRT1 levels, for this reason, may serve as a biomarker…
Engineers with Michigan State University (MSU) are developing diamond-based electrodes that might detect early warning signs of neurodegenerative diseases such as Parkinson’s in a living brain. MSU researchers Wen Li and Erin Purcell have received $3.4 million in funding from the National…
Supernus Pharmaceuticals has submitted a new drug application to the U.S. Food and Drug Administration (FDA) seeking approval of SPN-830, its apomorphine infusion pump, the company said. If approved, the pump will be used for the continuous treatment of on-off episodes in adults with Parkinson’s…
Sunovion‘s Kynmobi (apomorphine hydrochloride), a sublingual film treatment for “off” episodes in people with Parkinson’s disease, has a manageable safety profile and maintains efficacy over up to nearly a year of use, interim data from an ongoing Phase 3 trial show. Findings were presented at MDS…
Mutations in the PARK7 gene, known to cause early onset Parkinson’s disease, result in low levels of a protein called DJ-1 that is essential for nerve cell health, a study revealed. In fixing a protein processing malfunction in cells derived from members of…
Vercise Genus, a fourth-generation system for deep brain stimulation (DBS) made by Boston Scientific, has received CE marking and is now commercially available in Europe. A treatment approach for Parkinson’s disease, DBS involves surgically implanting a neurostimulator to deliver electrical impulses to targeted regions of…
Disturbed sleep, like that due to sleep apnea, significantly associates with poorer cognition in Parkinson’s disease patients, particularly in the domains of attention, executive function, and memory, a study reported. The study, “Sleep Disturbances and Sleep Disordered Breathing Impair Cognitive Performance in Parkinson’s Disease,” was published…
Get regular updates to your inbox.
